Ambrx Biopharma Cayman, Inc. Balance Sheet

Understand Stock

$11.33 +$1.08 (10.54%)

Deep Research with AI Research

Overview

Overview Financials SEC Filings Executives News

Specialized Tools

Valuations P Insider Transactions P Congressional Trades P

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q4	2022 Q2	2021 Q4	2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$235.1M 112.0% YoY	$157.5M N/A	$84.48M -50.32% YoY	$110.9M -33.68% YoY	$170.1M N/A	$167.2M N/A
Cash & Equivalents	$228.3M 247.74% YoY	$149.6M 4.14% YoY	$55.61M -67.3% YoY	$65.64M -60.74% YoY	$170.1M 86.31% YoY	$167.2M N/A
Short-Term Investments	$6.824M -84.92% YoY	$7.940M N/A	$28.87M N/A	$45.25M N/A	$0.00 N/A	N/A
Other Short-Term Assets	$981.0K -87.54% YoY	$238.0K N/A	$319.0K -94.09% YoY	$7.876M 59.43% YoY	$5.399M N/A	$4.940M N/A
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Prepaid Expenses	N/A	N/A	N/A	N/A	N/A	N/A
Receivables	$81.00K -94.47% YoY	$62.00K N/A	$376.0K -69.65% YoY	$1.466M 96.51% YoY	$1.239M N/A	$746.0K N/A
Other Receivables	$2.231M 189.36% YoY	$2.254M N/A	$1.674M 1509.62% YoY	$771.0K 442.96% YoY	$104.0K N/A	$142.0K N/A
Total Short-Term Assets	$241.4M 99.5% YoY	$162.9M N/A	$90.58M -48.77% YoY	$121.0M -30.07% YoY	$176.8M N/A	$173.0M N/A
LONG-TERM ASSETS
Property, Plant & Equipment	$3.195M -78.71% YoY	$2.889M N/A	$3.044M -80.64% YoY	$15.01M 407.47% YoY	$15.72M N/A	$2.957M N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Intangibles	$24.94M N/A	$25.09M N/A	$25.25M -29.79% YoY	N/A	$35.96M N/A	N/A
Long-Term Investments	$0.00 -100.0% YoY	$8.798M N/A	$16.79M N/A	$18.83M N/A	N/A	N/A
Other Assets	$357.0K -23.39% YoY	$380.0K N/A	$339.0K -36.04% YoY	$466.0K 15.92% YoY	$530.0K N/A	$402.0K N/A
Total Long-Term Assets	$38.53M -35.64% YoY	$47.67M N/A	$56.39M 8.01% YoY	$59.86M 47.1% YoY	$52.21M N/A	$40.70M N/A
TOTAL ASSETS
Total Short-Term Assets	$241.4M 99.5% YoY	$162.9M N/A	$90.58M -48.77% YoY	$121.0M -30.07% YoY	$176.8M N/A	$173.0M N/A
Total Long-Term Assets	$38.53M	$47.67M	$56.39M	$59.86M	$52.21M	$40.70M
Total Assets	$279.9M 54.78% YoY	$210.6M N/A	$147.0M -35.82% YoY	$180.9M -15.37% YoY	$229.0M N/A	$213.7M N/A
SHORT-TERM LIABILITIES
Accounts Payable	$6.362M 11.69% YoY	$7.107M N/A	$3.205M -39.21% YoY	$5.696M 51.17% YoY	$5.272M N/A	$3.768M N/A
Accrued Expenses	$9.556M -43.47% YoY	$6.782M N/A	$11.31M -24.77% YoY	$16.91M 79.8% YoY	$15.04M N/A	$9.402M N/A
Deferred Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Short-Term Debt	$0.00 N/A	$0.00 N/A	$0.00 N/A	$0.00 N/A	$0.00 N/A	$0.00 N/A
Long-Term Debt Due	N/A	N/A	N/A	N/A	N/A	N/A
Total Short-Term Liabilities	$18.18M -29.37% YoY	$16.09M N/A	$16.66M -32.22% YoY	$25.74M 47.21% YoY	$24.58M N/A	$17.48M N/A
LONG-TERM LIABILITIES
Long-Term Debt	$0.00 N/A	$0.00 N/A	$0.00 N/A	$0.00 N/A	$0.00 N/A	$0.00 N/A
Other Long-Term Liabilities	$10.51M -15.01% YoY	$11.05M N/A	$11.59M -14.76% YoY	$12.36M 382.06% YoY	$13.59M N/A	$2.564M N/A
Total Long-Term Liabilities	$10.51M -15.01% YoY	$11.05M N/A	$11.59M -14.76% YoY	$12.36M 382.06% YoY	$13.59M N/A	$2.564M N/A
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.18M -29.37% YoY	$16.09M N/A	$16.66M -32.22% YoY	$25.74M 47.21% YoY	$24.58M N/A	$17.48M N/A
Total Long-Term Liabilities	$10.51M -15.01% YoY	$11.05M N/A	$11.59M -14.76% YoY	$12.36M 382.06% YoY	$13.59M N/A	$2.564M N/A
Total Liabilities	$29.56M -24.15% YoY	$28.02M N/A	$29.13M -25.41% YoY	$38.98M 86.25% YoY	$39.05M N/A	$20.93M N/A
SHAREHOLDERS EQUITY
Retained Earnings	-$324.8M N/A	-$306.9M N/A	-$291.6M 36.51% YoY	N/A	-$213.6M N/A	N/A
Common Stock	$43.00K N/A	$39.00K N/A	$27.00K 0.0% YoY	N/A	$27.00K N/A	N/A
Preferred Stock	N/A	N/A	N/A	N/A	N/A	N/A
Treasury Stock (at cost)	N/A	N/A	N/A	N/A	N/A	N/A
Treasury Stock Shares	N/A	N/A	N/A	N/A	N/A	N/A
Shareholders Equity	$250.4M 76.46% YoY	$182.6M 8.06% YoY	$117.9M -37.96% YoY	$141.9M -26.4% YoY	$190.0M -236.24% YoY	$192.8M N/A
Total Liabilities & Shareholders Equity	$279.9M 54.78% YoY	$210.6M N/A	$147.0M -35.82% YoY	$180.9M -15.37% YoY	$229.0M N/A	$213.7M N/A